Patents by Inventor Matt Trau

Matt Trau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220120745
    Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.
    Type: Application
    Filed: August 27, 2021
    Publication date: April 21, 2022
    Applicants: The University of Queensland, Seattle Children's Hospital dba Seattle Children's Research Institute
    Inventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J.A. Shiddiky, Matt Trau
  • Publication number: 20220033880
    Abstract: Disclosed is an epigenetic biomarker that comprises clustered methylated genomic DNA which can self-assemble to form complexes that have distinct physicochemical properties relative to genomic DNA that lacks such clusters. Also disclosed are methods, systems, compositions and kits that takes advantage of these physicochemical properties for detecting clustered methylated genomic DNA including for determining likelihood of the presence of cancer.
    Type: Application
    Filed: October 17, 2019
    Publication date: February 3, 2022
    Inventors: Abu SINA, Matt TRAU, Laura GARCIA CARRASCOSA
  • Patent number: 11105802
    Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 31, 2021
    Assignees: SEATTLE CHILDREN'S HOSPITAL, The University of Queensland
    Inventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J. A. Shiddiky, Matt Trau
  • Patent number: 10465236
    Abstract: A method and kit for detecting a target nucleic acid is provided wherein combining an amplified nucleic acid with a particle such as a paramagnetic bead form a flocculated complex which can be detected by visual inspection. The volume of nucleic acid sample that can be detected is as low as a few microlitres. The method can be applied to in-the-field or point-of-care diagnosis for a rapid determination of the presence or absence of the target nucleic acid. The methylation status of a target nucleic acid can also be determined. The method and lit may have general applicability to detecting diseases in plants and animals, environmental testing and testing for contamination of foods and other edible products.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: November 5, 2019
    Assignee: University of Queensland
    Inventors: Matt Trau, Eugene Wee, Jose Ramon Botella
  • Patent number: 10156546
    Abstract: A device for the detection of target entities, the device including: a fluidic channel to conduct a liquid sample containing at least one type of target entity to be detected; and mutually spaced electrodes disposed along the fluidic channel; wherein the mutually spaced electrodes are functionalized to selectively bond to the at least one type of target entity and are configured to electro-hydrodynamically pump the liquid sample along the fluidic channel on application of a signal to the electrodes, such that selectivity of attachment of the at least one type of target entity to the electrodes is determined by at least one parameter of the signal.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: December 18, 2018
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Matt Trau, Muhammad Johirul Alam Shiddiky, Sakandar Rauf, Ramanathan Pudhukode Vaidyanathan
  • Patent number: 9791436
    Abstract: A biosensor molecule comprises: a protease amino acid sequence; at least one sensor comprising at least one sensor amino acid sequence which is responsive to at least one target molecule; and an inhibitor of the protease activity of said protease amino acid sequence; wherein the biosensor is switchable from a protease active to a protease inactive state, or from a protease inactive to a protease active state when said sensor responds to said target molecule. The biosensor protease may be a protease of a virus such as a Potyvirus or a Flavivirus wherein the inhibitor is an autoinhibitory peptide derived from the virus. The biosensor may respond to the target molecule allosterically or may be cleaved by a target protease molecule.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 17, 2017
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Kirill Alexandrov, Viktor Stein, Matt Trau
  • Publication number: 20170029881
    Abstract: A method and kit for detecting a target nucleic acid is provided wherein combining an amplified nucleic acid with a particle such as a paramagnetic bead form a flocculated complex which can be detected by visual inspection. The volume of nucleic acid sample that can be detected is as low as a few microlitres. The method can be applied to in-the-field or point-of-care diagnosis for a rapid determination of the presence or absence of the target nucleic acid. The methylation status of a target nucleic acid can also be determined. The method and lit may have general applicability to detecting diseases in plants and animals, environmental testing and testing for contamination of foods and other edible products.
    Type: Application
    Filed: December 23, 2014
    Publication date: February 2, 2017
    Inventors: Matt TRAU, Eugene WEE, Jose Ramon BOTELLA
  • Publication number: 20160003771
    Abstract: A device for the detection of target entities, the device including: a fluidic channel to conduct a liquid sample containing at least one type of target entity to be detected; and mutually spaced electrodes disposed along the fluidic channel; wherein the mutually spaced electrodes are functionalised to selectively bond to the at least one type of target entity and are configured to electro-hydrodynamically pump the liquid sample along the fluidic channel on application of a signal to the electrodes, such that selectivity of attachment of the at least one type of target entity to the electrodes is determined by at least one parameter of the signal.
    Type: Application
    Filed: February 19, 2014
    Publication date: January 7, 2016
    Inventors: Matt TRAU, Muhammad Johirul Alam SHIDDIKY, Sakandar RAUF, Ramanathan PUDHUKODE VAIDYANATHAN
  • Publication number: 20150377880
    Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.
    Type: Application
    Filed: December 10, 2013
    Publication date: December 31, 2015
    Applicants: Seattle Biomedical Research Institute, The University of Queensland
    Inventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J.A. Shiddiky, Matt Trau
  • Publication number: 20150226731
    Abstract: A biosensor molecule comprises: a protease amino acid sequence; at least one sensor comprising at least one sensor amino acid sequence which is responsive to at least one target molecule; and an inhibitor of the protease activity of said protease amino acid sequence; wherein the biosensor is switchable from a protease active to a protease inactive state, or from a protease inactive to a protease active state when said sensor responds to said target molecule. The biosensor protease may be a protease of a virus such as a Potyvirus or a Flavivirus wherein the inhibitor is an autoinhibitory peptide derived from the virus. The biosensor may respond to the target molecule allosterically or may be cleaved by a target protease molecule.
    Type: Application
    Filed: September 12, 2013
    Publication date: August 13, 2015
    Inventors: Kirill Alexandrov, Viktor Stein, Matt Trau
  • Publication number: 20110312613
    Abstract: A carrier pre-encoded with information sufficient to distinguish it from a heterogeneous population of carriers is disclosed on which a compound can be synthesised. The carrier has two attributes integrally associated therewith, which attributes are detectable and/or quantifiable during synthesis of the compound and which define a code identifying the carrier before, during and after said synthesis, with the proviso that one of said attributes is other than shape, or surface deformation(s) of the carrier. The invention also encompasses a plurality of carriers that are pre-encoded as above and a method of synthesising and deconvoluting a combinatorial library using such carriers.
    Type: Application
    Filed: May 13, 2011
    Publication date: December 22, 2011
    Applicant: NANOMICS BIOSYSTEMS PTY LTD
    Inventors: Bronwyn Jean Battersby, Darryn Edward Bryant, Matt Trau
  • Patent number: 5023081
    Abstract: Controlled release microspheres of hydroxybutyrate polymer comprise active ingredient and hydroxybutyrate/hydrovalerate copolymer. The microspheres comprise a skin which is distinct from the general bulk of the microspheres, and this skin may have a porosity covering from 0-50% of the total surface area of the microsphere, this porosity being largely controlled by varying the hydroxyvalerate content of the polymer. The porosity of the interior of the microspheres can also be regulated. Control of the two porosities permits the attainment of a wide range of release rates for a wide range of active ingredients. The microspheres can be used in a wide variety of pharmaceutical, veterinary and agricultural applications.
    Type: Grant
    Filed: January 27, 1989
    Date of Patent: June 11, 1991
    Assignee: ICI Australia Operations Proprietary Limited
    Inventors: Matt Trau, Rowan W. Truss